Drug Profile
SPH 1188 11
Alternative Names: I-010; SPH1188; SPH1188-11Latest Information Update: 04 May 2022
Price :
$50
*
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 30 Mar 2022 SPH 1188 11 is still in phase I trials for Non-small cell lung cancer in China
- 31 Dec 2020 Shanghai Pharmaceuticals withdrew a phase I trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO), based on board decision (NCT03231475)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)